TherapeuticsMD, Inc.

For the period ended Jun 30, 2026. Filed Aug 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 11, 2026

TXMD$1.74+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(Unaudited - in thousands, except per share data)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Revenue, net:
License revenue	$869	$952	$1,593	$1,345
Operating expenses:
General and administrative	1,577	1,551	2,930	3,042
Write-off of patents	13	-	13	88
Depreciation & amortization	95	96	189	191
Total operating expenses	1,685	1,647	3,132	3,321
Loss from operations	(816)	(695)	(1,539)	(1,976)
Other income:
Interest income, net	69	29	110	59
Sublease income	523	376	1,040	786
Miscellaneous income	388	835	656	1,008
Total other income, net	980	1,240	1,806	1,853
Income (loss) from continuing operations before income taxes	164	545	267	(123)
Income tax benefit	-	-	-	32
Income (loss) from continuing operations, net of income taxes	164	545	267	(91)
Income (loss) from discontinued operations, net of income taxes	(9)	6	(17)	(11)
Net income (loss)	$155	$551	$250	$(102)
Income (loss) per common share, basic and diluted:
Continuing operations	$0.01	$0.05	$0.02	$(0.01)
Discontinued operations, net	(0.00)	0.00	(0.00)	(0.00)
Net income (loss) per common share, basic and diluted	$0.01	$0.05	$0.02	$(0.01)
Weighted average common shares, basic	11,574	11,574	11,574	11,563
Weighted average common shares, diluted	11,643	11,574	11,644	11,563

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.